Harlow John B. Jr. reported grant involving 50,000 shares of Larimar Therapeutics, Inc. at $0.00 for $0 on Sep 29, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
President and COO
President and COO
Filed Oct 1, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
50,000Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
50,000Direct
Trade date
Sep 29, 2026Grant
Filed
Oct 1, 2026, 4:27 PM ET2-day reporting delay
Accession
0001193125-26-410719Code A · Transaction 232934
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 29, 2026Grant800,000$0.00$0Trade 232935
2 transaction rows in this filing. Joint filers share the same rows.

LRMR price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
LRMR · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +31%1w ago +25%1d ago +3.6%
Returns since7d −12%30d −19%90d180d1y

Footnotes in full

F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F2: The option vests 25% on September 29, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.